A clinicopathologic study of malignant melanoma based on cytomorphology

Radhika, K; Ak, Prayaga; Challa, Sundaram

doi:10.4103/0019-509x.180822

Cited by 10 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our experience, focal necrosis was seen in only 1 melanoma case. Radhika et al found melanin pigment in 77% cases, which is less as compared to our study. The most common pattern seen in their study was spindle (67%) unlike our study where predominant morphology was of epithelioid type (80.4%).…”

Section: Discussioncontrasting

confidence: 97%

“…Not many studies have described the cytomorphological spectrum of melanoma in detail. Radhika et al found 67% of spindle morphology, which was discordant with our results where the majority was of epithelioid morphology . Gupta et al studied 23 cases and found predominant epithelioid morphology .…”

Section: Discussionsupporting

confidence: 72%

“…Among the secondary sites of involvement, the inguinal lymph node was the most common site for metastases as seen in other studies. 24 Radhika et al 23 observed 3% of uveal melanoma in their study, which was less than that observed in our study (11.1%). Bianciotto et al 24 in their study reported 20% uveal melanomas.…”

Section: Cytologymentioning

confidence: 99%

“…Radhika et al found 67% of spindle morphology, which was discordant with our results where the majority was of epithelioid morphology. 23 Gupta Local or distant metastasis is usually present in about 10% of melanoma patients, 25 and these patients have a much poorer survival. 4,6,7 Patients with regional lymph node metastases have 5-and 10-year survival rates of 49 and 37%, respectively.…”

Section: Cytologymentioning

confidence: 99%

See 3 more Smart Citations

The spectrum of malignant melanoma on cytology: A tertiary care center study

Kapatia

Gupta

Rohilla

et al. 2019

Diagnostic Cytopathology

View full text Add to dashboard Cite

Introduction Malignant melanoma accounts for around 3% of all malignancies. Fine‐needle aspiration cytology (FNAC) is a convenient diagnostic procedure for the diagnosis of melanoma and its metastases. Aim To explore the cytological spectrum of malignant melanoma including the rare metastatic sites. Material and Methods A total of 51 patients of malignant melanoma or its metastases on FNAC were studied over a period of 5 years. The FNAC smears of these cases were analyzed in detail by two different observers (GC and PD). Results Among the 51 patients studied, the mean age was 54 years (range 19‐97 years). Male‐to‐female ratio was 1.04:1 with 25 females and 26 males. The commonest primary site of the melanoma cases was lower extremity. The inguinal lymph node was the most common site for metastasis. Melanin pigment was the predominant feature followed by prominent nucleoli. Epithelioid pattern was the predominant shape. Conclusion Cytopathologists must be aware of the wide range of morphological spectrum seen in the cases of melanoma for a greater accuracy in diagnosis and to circumvent pitfalls in diagnosing melanoma.

show abstract

Section: Discussioncontrasting

confidence: 97%

Section: Discussionsupporting

confidence: 72%

Section: Cytologymentioning

confidence: 99%

Section: Cytologymentioning

confidence: 99%

See 2 more Smart Citations

The spectrum of malignant melanoma on cytology: A tertiary care center study

Kapatia

Gupta

Rohilla

et al. 2019

Diagnostic Cytopathology

View full text Add to dashboard Cite

show abstract

“…2 In this purpose, a preoperative diagnosis is mandatory which is best achieved through fine-needle aspiration technique. 7 Likewise, the lip mass discussed here and its in-transit deposits were easily diagnosed on cytology. Successive histopathology confirmed the diagnosis.…”

Section: Nodular Melanoma On Lip With Retrograde In-transit Metastases On Facementioning

confidence: 74%

Nodular melanoma on lip with retrograde in-transit metastases on face

Mondal¹,

Mandal²

2021

IJDVL

View full text Add to dashboard Cite

show abstract

Early Experience with Dabrafenib–Trametinib Combination in Patients with BRAF-Mutated Malignant Melanoma—A Single-Center Experience

Ganguly

Ghosh

Mishra

et al. 2021

South Asian J Cancer

View full text Add to dashboard Cite

Background Combination of dabrafenib–trametinib is one of the standard treatments in patients with BRAF-mutated advanced malignant melanoma (MM). Real-world data on the usage of this combination is scarce, especially from India. Here, we are reporting our early experience with the usage of this combination therapy. Materials and Methods This is a single institutional data assessment of patients with BRAF-mutated MM registered and treated with BRAF–MEK inhibitors in our hospital. Clinico-pathological features and treatment details were reviewed for all patients. Results A total of seven patients with BRAF-mutated MM treated with this combination therapy with a median age of 66.5 years (range: 49–72 years) and a male:female ratio of 3:4. Six (85.7%) patients had metastatic disease at presentation. In total, 80% of our patient population had two or less than two sites of metastasis at presentation. The initial response rate of the study population was 71%. The drug was well tolerated with fever being the most common side effect which was seen in two (28.5%) of the patients. Conclusion Combination of dabrafenib–trametinib is effective in patients with BRAF-mutated MM with good tolerability. Further studies are required to look for improvement in outcome in this group of patients.

show abstract

A clinicopathologic study of malignant melanoma based on cytomorphology

Abstract: A spectrum of cytomorphological features in correlation with clinical details leads to greater precision in diagnosis and helps to avoid pitfalls in diagnosing melanoma.

Cited by 10 publications

References 0 publications

The spectrum of malignant melanoma on cytology: A tertiary care center study

The spectrum of malignant melanoma on cytology: A tertiary care center study

Nodular melanoma on lip with retrograde in-transit metastases on face

Early Experience with Dabrafenib–Trametinib Combination in Patients with BRAF-Mutated Malignant Melanoma—A Single-Center Experience

Contact Info

Product

Resources

About